Floatz logo

FLUOROURACILUM

C04.588.274.476.411.307

Chung Shan Medical UniversitySmall moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the C04.588.274.476.411.307 cohort.

Asset / SponsorPhaseRating
Capecitabine
Brigham and Women's Hospital
Phase 4BB
Eloxatin
Chung Shan Medical University
Phase 2/3BB
Irinotecan
Cornerstone Pharmaceuticals
Phase 1CC
(+)-VINCRISTINE
Cornerstone Pharmaceuticals
Phase 1CC
Calcium folinate pentahydrate
Chung Shan Medical University
Phase 1CC
Devimistat
Cornerstone Pharmaceuticals
Phase 1CC

Same molecule, other indications

FLUOROURACILUM is also rated in:

colon carcinomaDormant
A
Indicative ·
82 / 100
View asset →
Unresectable or Metastatic Colorectal CancerDormant
BBB
Indicative ·
79 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →